Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top 20 Journal Cited
 » Top 20 Cited
 » Top 20 Author Cited
 » Usage Since Sept 2007


 
 
 

Login | Create Account

The utility of Hepatocyte Paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma

Isa M R, and Shiran M. S., and Sherina M.S., and Rampal, L., and Hairuszah I, and Sabariah A.R. , (2006) The utility of Hepatocyte Paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma. Malaysian Journal of Pathology, 28 (2). pp. 87-92. ISSN 0126-8635

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
448Kb

Official URL: http://www.mjpath.org.my

Affiliations

Universiti Putra Malaysia. Faculty of Medicine and Health Science. Dept. of Pathology
Universiti Kebangsaan Malaysia. Faculty of Medicine. Dept. of Pathology
Universiti Putra Malaysia. Faculty of Medicine and Health Science. Dept. of Community Health

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and its diagnosis on routine stains is usually straightforward, except in some cases where there may be difficulty in distinguishing HCCs from metastatic carcinomas (MC) and cholangiocarcinomas (CC). Hepatocyte Paraffin 1 antibody (Hep Par 1) is a new monoclonal antibody which reacts with normal and neoplastic hepatocytes, and this study aims to determine its specificity and sensitivity in distinguishing hepatocellular carcinoma (HCC) from cholangiocarcinoma (CC) and metastatic carcinomas (MC). Hep Par 1 antibody was applied to 28 cases of HCC, 22 cases of MC from varying sites and 8 CCs, and produced a strong, diffuse, granular, cytoplasmic staining of all benign hepatocytes. 23 out of 28 cases of HCC showed heterogeneously positive staining for Hep Par 1 irrespective of their degree of differentiation, while 2 out of 8 cases of cholangiocarcinoma were positive for Hep Par 1, and all 22 cases of metastatic carcinoma were negative. The sensitivity and specificity of Hep Par 1 for HCC was 82.1 % and 93.3 % respectively; whereby the antibody was noted to show occasional false positivity in cases of cholangiocarcinoma and non-neoplastic bowel mucosa, while its variable staining in HCC produced false negative results in some small biopsies. Thus, Hep Par 1 should be used in a panel with other antibodies to obtain useful information in distinguishing HCC from CC and MC.

Item Type:Journal
Keywords:Hep Par 1 antibody, hepatocellular carcinoma, metastatic carcinoma, cholangiocarcinoma.
Subjects:R Medicine
ID Code:1767

Robbins SL, Cotran RS, Kumar V, Collins T : Liver and biliary tract. In: Robbins Pathologic Basis of Disease. 4th edition, W.B. Saunders Co.; 1989: 958-962.

Juan Rosai: Liver. In: Ackerman’s Surgical Pathology, Volume 1. 8th Edition. Mosby; 1996: 903-911.

Leong AS-Y, Sormunen RT, Tsui WMS, Liew CT. Hep Par 1 and selected antibodies in the immunohistological

distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998; 33: 318-24.

Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte

paraffin 1: A monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumours. Am J Pathol. 1993; 143: 1050-4.

Thung SN, Gerber MA, Sarno E, Poper H. Distribution

of 5 antigens in hepatocellular carcinoma. Lab Invest 1979; 41: 101-5.

Brumm C, Sholze C, Charles K et al. The significance

of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology 1989; 14: 503-13.

Hurlimann J and Gardiol O. Immunohistochemistry in the differential diagnosis of liver carcinoma. Am J Surg Pathol 1991; 15(3): 280-8.

Ferrandez-Izquierdo A, Llombart-Bosch A. Immunohistochemical

characterization of 130 cases of primary hepatic carcinomas. Pathol Res Pract 1987; 182: 783-91.

Parvin G, Muhrad N, Jooge AS, Azorides RM. Histologic

markers in primary and metastatic tumours of the liver. Cancer 1988; 62: 1994-8.

Fucich LF, Cheles MK, Thung SN, Gerber MA, Marrogi AJ. Primary vs metastatic hepatic carcinoma.

An immunohistochemical study of 34 cases. Arch Pathol. Lab. Med 1994; 118: 927-30.

Ma CK, Zarbo RJ, Frierson Jr., HF Lee MW. Comparative

immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Path 1993; 99: 551-7.

Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma.

Am J Surg Pathol 1988; 12(3): 187-7.

Balaton AJ, Nehama-Sibony M, Gotheil C. Distinction

between hepatocellular carcinoma, cholangiocarcinoma,

and metastatic carcinoma based on immunohistochemical

staining for carcinoembryonicJ Pathol 1988; 156: 305-10.

Koelman IJ, Nap M, Huitema S et al. Hepatocellular carcinoma, adenoma and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical

parameters. Arch Pathol Lab Med 1986; 110: 1035-40.

Murukata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical

study with renal cell carcinoma. Mod Pathol 2001; 13: 874-81.

Ishikura H, Kishimoto T, Andachi H, Kakuta Y, Yoshiki

T. Gastrointestinal hepatoid adenocarcinoma: venous permeation and mimicry of hepatocellular carcinoma, a report of four cases. Histopathology 1997; 31: 47-54.

Johnson DE, Powers CN, Rupp G et al. Immunocytochemical

staining of fine needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma. Mod Pathol 1992; 5: 117-23.

Lamps, LW, Folpe AL. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumours: A review. Adv Anat Pathol 2003; 10(1): 39-43

Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma. An immunohistochemical comparison to carcinoembryonic

antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002; 26: 978-88.

Fan, Zhen M.D.; van de Rijn, Matt M.D., Ph.D.; Montgomery, Kelli; Rouse, Robert V. M.D. Hep Par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumours tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003; 16(2): 137-44.

Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA. Utilization of hepatocyte-

specific antibody in the immunocytochemical evaluation of liver tumours. Mod Pathol 1997; 10: 686-92.

Kumagai I, Masuda T, Sato S, Ishikawa K. Immunoreactivity

to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histologic pattern. Hepatol Res 2001; 20: 312-39.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.